#United States #Caris Life Sciences #Little Rock #Precision Oncology #UAMS Cancer Institute

Caris Life Sciences Welcomes UAMS Winthrop P. Rockefeller Cancer Institute to Its Precision Oncology Alliance

On December 2, 2025, Caris Life Sciences® (NASDAQ: CAI), a frontrunner in patient-centric AI technology and precision medicine, proudly announced the inclusion of the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute in the Caris Precision Oncology Alliance™ (Caris POA). This collaborative network, which boasts some of the world's leading cancer centers and research groups, is designed to advance the sophisticated field of precision oncology and the research of biomarkers that guide treatment choices.

Dr. James Hamrick, Chairman of the Caris POA, emphasized the significance of UAMS's admission, stating, "It is great to welcome UAMS to the Caris POA. Their unwavering commitment to excellence perfectly aligns with our commitment to advance biomarker-driven precision oncology." This partnership aims to utilize shared data and cutting-edge AI technology to accelerate research in the pursuit of personalized patient care, not only in Arkansas but across the globe.

Collaboration Focused on Patient Care

The main objective of the Caris POA is to establish and enhance standards for molecular testing through extensive collaborative research initiatives that aim to improve outcomes for cancer patients. Utilizing Caris’s innovative AI-driven bioinformatics and machine learning tools, the alliance aims to streamline discovery processes and translate research findings into actionable health strategies. The partnership will empower both institutions to offer enhanced precision care through well-informed decision-making backed by comprehensive data.

The Winthrop P. Rockefeller Cancer Institute, located in Little Rock, Arkansas, positions itself as a premier center for cancer research and treatment. Staffed by nationally recognized experts, the institute delivers comprehensive, research-driven care to a diverse range of patients grappling with both common and rare complex diseases. Dr. Michael Birrer, director of the UAMS Cancer Institute, noted, "Joining the Caris Precision Oncology Alliance strengthens our ability to bring the most advanced, data-driven cancer care to patients in Arkansas and beyond. This collaboration allows us to contribute to, and benefit from, a global network of leading institutions using precision medicine to accelerate discoveries and deliver truly personalized cancer treatment."

Expanding a Global Network

With UAMS’s addition, the Caris POA has expanded its network to include 98 distinguished cancer centers, academic institutions, and healthcare systems - including 45 National Cancer Institute-designated centers. This large network collaborates to further the advancements in precision oncology and the research into biomarkers, which play a vital role in customizing treatment for patients. Through Caris’s molecular profiling services, which incorporate a broad spectrum of genomic, transcriptomic, and proteomic information, the alliance endeavors to prioritize therapeutic alternatives and facilitate access to beneficial clinical trial opportunities.

Caris POA members also gain entry to an expansive and intricate multi-modal database that comprises matched molecular and clinical outcome data from hundreds of thousands of cancer patients, affording them access to one of the industry’s richest repositories of information. This invaluable resource contains tens of billions of data points per patient to facilitate comprehensive analyses.

About Caris Life Sciences

Founded with the vision of leveraging precision medicine to better human health, Caris Life Sciences® is at the forefront of AI-driven health tech. Headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge, Tokyo, and Basel, the company remains committed to developing advanced molecular profiling techniques and innovative solutions transforming healthcare. Their focus on integrating AI and machine learning with next-generation sequencing helps carve pathways for early detection, diagnosis, treatment selection, and drug development specific to various medical conditions.

In conclusion, the collaboration between Caris Life Sciences and the UAMS Winthrop P. Rockefeller Cancer Institute represents a significant leap in the quest for more effective cancer treatments and emphasizes the essence of partnerships in the modern medical landscape. Together, they aim to unlock new methodologies that promise to enhance the experience and outcomes for cancer patients not just in Arkansas, but worldwide.